Bcr-Abl (b2a2 Junction Specific) Mouse Monoclonal Antibody
No Size Price Availability  
AMMM007-21 50ul 1500.00 In Stock
AMMM007-21 100ul 2000.00 In Stock
  • Details
  • FAQs
  • Manual
Source: Mouse Gene Id: /
Isotype: IgG2a Swiss Prot: /
purity: Affinity purification
Background:
The Bcr gene was orginally identified by its presence in the chimeric Bcr-Abl oncogene (1). The amino-terminal region of Bcr contains an oligomerization domain, a serine/threonine kinase domain, and a region that binds SH2 domains. The middle of the protein has a PH domain and a region of sequence similarity to the guanine nucleotide exchange factors for the Rho family of GTP binding proteins. The carboxy-terminal region may be involved in a GTPase activating function for the small GTP-binding protein Rac (2,3). The function of wild type Bcr in cells remains unclear. PDGF receptor may use Bcr as a downstream signaling mediator (4). Research studies have shown that the Bcr-Abl fusion results in production of a constitutively active tyrosine kinase, which causes chronic myelogenous leukemia (CML) (5). Tyr177 of Bcr is phosphorylated in the Bcr-Abl fusion protein, which plays an important role in transforming the activity of Bcr-Abl (6). Phosphorylated Tyr177 provides a docking site for Gab2 and GRB2 (7,8).The fusion protein encoded by Bcr-Abl varies in size, depending on the breakpoint in the BCR gene. Three breakpoint cluster regions have been characterized to date: major (M-bcr), minor (m-bcr) and micro (mu-bcr). The overwhelming majority of CML patients have a p210 Bcr-Abl gene (M-bcr), whose mRNA transcripts have a b3a2 and/or a b2a2 junction. The smallest of the fusion proteins, p190 Bcr-Abl, (m-bcr breakpoint) is principally associated with Ph-positive ALL. Rare cases of CML are due to a p190-type of Bcr-Abl gene and in these, the disease tends to have a prominent monocytic component, resembling CMML. CML resulting from a p230 Bcr-Abl gene (mu-bcr breakpoint) is also rare, and has been associated with the CNL variant and/or with marked thrombocytosis. Exceptional CML cases have been described with Bcr breakpoints outside the three defined cluster regions, or with unusual breakpoints in Abl (9).
Reactivity Human
Tested applications WB
Clonality Monoclonal Antibody
Calculated MW 210 kDa
Recommended Dilutions
WB 1:1000
Immunogen A synthetic peptide corresponding to the b2a2 junction site sequence of human Bcr-Abl
Storage Store at -20°C in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Avoid freeze/thaw cycles.
Synonym /
This product is for research use only, not for diagnostic or therapeutic use!

backtop
QQ
service center
Contact Us